Pearl Freier

45K posts

Pearl Freier

Pearl Freier

@PearlF

Founder of Cambridge BioPartners, Inc.

Cambridge, MA USA Katılım Mart 2009
6.2K Takip Edilen10.4K Takipçiler
Pearl Freier retweetledi
Jonathan LaPook, M.D
Jonathan LaPook, M.D@DrLaPook·
On this Memorial Day weekend, I’m thinking about my father, a WWII veteran who landed at Utah Beach and served with General Patton. When he was 97, he tried to re-enlist!!! Listen to what happened.
English
1
7
42
2.3K
Pearl Freier
Pearl Freier@PearlF·
On Memorial Day and every day, I’m grateful for the heroic men and women who gave their lives serving our country. Keeping them, their families, and loved ones in my thoughts.
English
0
0
8
630
Pearl Freier
Pearl Freier@PearlF·
"This award is one of the only paths that gives a tiny number of exceptional PhD or clinical trainees the funding to launch their own research groups directly, rather than spending many years in a postdoc first." @chorye wrote in thread below
Emma J Chory@chorye

This one is hard to see. The NIH Early Independence Award, one of the most competitive grants in the country for young scientists, will not go forward in FY2026. NIH says this is due to “administrative changes to funding opportunity processing and delays in approvals.”

English
0
0
0
1.2K
Pearl Freier retweetledi
⚪️ sierra catalina
⚪️ sierra catalina@sierracatalina·
sooooo 𝕏 isn’t indexing your long form content. at all. your articles are not indexed anywhere. therefore they are not discoverable to ANY AI or web search anymore INCLUDING GROK.
English
89
24
904
83.9K
Pearl Freier retweetledi
Pearl Freier retweetledi
Seth Bannon
Seth Bannon@sethbannon·
Are they trying to destroy our innovation economy? We have employees in the US legally applying for permanent residency. Now they can't work with us while they wait for an answer? Immigrant founders building companies here applying for green cards have to leave? Insanity.
USCIS@USCIS

USCIS is applying long-standing law and prior court decisions to require certain aliens with temporary visas who decide they want to permanently reside in the U.S. to return to their home countries to apply for permanent visas through the @StateDept. We're returning to the original intent of the law to ensure aliens navigate our nation’s immigration system properly. Here’s what you should know: uscis.gov/newsroom/news-…

English
237
80
488
37.1K
Pearl Freier retweetledi
Drew Volpe
Drew Volpe@drewvolpe·
"despite immigrants only making up 16% of inventors, they are responsible for 30% of aggregate US innovation since 1976" Making it even harder for the best science and engineering talent to come to US is an own goal.
Homeland Security@DHSgov

An alien who is in the U.S. temporarily and wants a Green Card must return to their home country to apply. This policy allows our immigration system to function as the law intended instead of incentivizing loopholes. The era of abusing our nation’s immigration system is over.

English
125
21
175
16.4K
Pearl Freier retweetledi
Andrew Ng
Andrew Ng@AndrewYNg·
The new White House policy requiring green card applicants to apply from outside the US is a capricious attack on legal immigration. It will hurt families, leave us with fewer doctors, teachers and scientists, and hurt American competitiveness in AI.
English
2.7K
1.6K
12K
1.3M
Pearl Freier
Pearl Freier@PearlF·
It's really unbelievable. What's the statistic about the Fortune 500 & how many CEOs & founders are either immigrants or have parents or grandparents who are immigrants. The US is only 250— most of the country probably has family members who immigrated to the US within the last 40-125 yrs.
English
0
0
2
351
villi
villi@villi·
To ensure our continued success and prosperity, we need a YIMBY-like movement for immigration, especially skilled immigration. The tech people around the administration have failed us.
English
52
6
122
14.6K
Thoughts on Healthcare Markets and Tech
The question the post raises but doesn't answer: why did that specific method work, and what exactly would need to be true for it to generalize across the technical approaches being lumped together under "AI drug discovery"? My read is that the Phase 3 result doesn't validate a field, it validates a stack, and the problem is that almost no one in the coverage cycle is willing to do the unglamorous work of specifying which stack. When I mapped the capital and technical differentiation in this space, I found at least four distinct lanes with genuinely different model classes, data dependencies, and failure modes, meaning a Phase 3 outcome in one lane tells you almost nothing about the probability distribution in another. The Insilico rentosertib Phase 2 readout in IPF (published in Nature Medicine, June 2025) is the clearest prior data point for what clinical validation from a fully AI-discovered, AI-designed asset actually looks like, and even that result sits in a very specific immunofibrotic biology context with a very specific generative chemistry and target ID pipeline behind it (PandaOmics plus Chemistry42, for anyone tracking the actual mechanism rather than the headline). A single Phase 3 approval is not a stress test for the field. It's a stress test for one company's integration of proprietary data generation, generative chemistry, and clinical translation, which is exactly why the question of generalizability is harder than most takes are allowing. onhealthcare.tech/p/the-ai-drug-…
Pearl Freier@PearlF

"one [AI-designed] drug cleared Phase 3 in December 2025. one. after decades of promises. the field should be asking precisely why that method worked rather than assuming it validates everything else." More below:

English
1
0
1
326
Pearl Freier retweetledi
Ohad Hammer
Ohad Hammer@ohadhammer·
Nevertheless the two most promising abstracts imo were from US-originated ADCs: $ABBV's STEAP1/PSMA - 67% PSA50 and 45% confirmed ORR in heavily pretreated prostate cancer $LLY's NECTIN4 - 48% ORR in bladder cancer including 40% ORR in Padcev failures asco.org/abstracts-pres… asco.org/abstracts-pres… #ASCO26
Ohad Hammer@ohadhammer

I counted 31 titles with a topo1 ADC in P1, 23 of which have been created and developed in China 🤯 Could find only a handful of "western" ADCs from Abbvie, Lilly and Merck KGa plus some rare cases of ADCs developed by European biotechs. #ASCO26

English
2
11
60
17K
Pearl Freier retweetledi
Helen Branswell 🇨🇦
Helen Branswell 🇨🇦@HelenBranswell·
Yet another top job in the #HHS universe appears to be vacant. Jeffery Taubenberger, who has been acting head of #NIAID, the infectious diseases institute of #NIH, reportedly stepped down ~2 weeks ago. But HHS will not answer questions about his departure. statnews.com/2026/05/21/nih…
English
5
57
84
14.6K
Pearl Freier retweetledi
Gerry Smith
Gerry Smith@gerryfsmith·
New: US officials are working with a small biotech company, Mapp Biopharmaceutical, to provide an experimental treatment that may be used in patients exposed to Ebola. google.com/url?q=https://…
English
0
1
3
458
Pearl Freier
Pearl Freier@PearlF·
Below is a top priority at the FDA according to the acting commissioner. No mention so far of meetings or calls with Huntington's disease or cancer groups? Why are they stalled on the pancreatic cancer drug Ben Sasse received in clinical trials? They can't do an EUA? #pancsm
Paige W. Cunningham@pw_cunningham

Diamantas told anti-abortion activists on his first day as acting FDA commissioner he would convene a group of scientists and clinical reviewers to assess the status of a promised-but-delayed safety study on mifepristone. First byline w @ReporterOriana ! notus.org/healthcare/ant…

English
0
4
10
3.2K
Pearl Freier
Pearl Freier@PearlF·
*I know I shouldn't be surprised by something like that anymore but I am
English
0
0
0
201